In short
A groundbreaking clinical trial is underway to assess the potential of BJT-778, a new drug developed for patients with chronic hepatitis B and D infections. This Phase 1/2a study aims to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of BJT-778 in both healthy volunteers and individuals with chronic hepatitis B, including those with chronic hepatitis D infection. The trial represents a significant step forward in the search for effective treatments for these persistent viral infections.
At a glance
- Study Type
- Phase 1/2a, Randomized, Placebo-Controlled
- Drug Name
- BJT-778
- Administration
- Subcutaneous injection
- Target Conditions
- Chronic Hepatitis B and D infections
- Primary Objective
- Evaluate safety and tolerability
- Secondary Objectives
- Assess pharmacokinetics, immunogenicity, antiviral activity against HBV and HDV, effect on ALT levels
- Key Inclusion Criteria
- Adults 18-70 years, chronic HBV infection, specific HBsAg levels, on stable nucleos(t)ide analog treatment
- Key Exclusion Criteria
- Cirrhosis, significant liver enzyme abnormalities, other liver diseases, recent malignancy
- Primary Endpoint
- Incidence of treatment-emergent adverse events and significant lab abnormalities
- Key Secondary Endpoints
- Pharmacokinetic parameters, antidrug antibody development, reductions in HBsAg and HDV RNA levels
What is BJT-778?
BJT-778 is a new investigational drug being developed by Bluejay Therapeutics, Inc. It is currently undergoing clinical trials to evaluate its safety, effectiveness, and how it works in the body for treating chronic hepatitis B and chronic hepatitis D infections. BJT-778 is a protein-based medication that is given as a solution for injection.
Medical Conditions Treated
BJT-778 is being studied for the treatment of two main conditions:
- Chronic Hepatitis B Infection: This is a long-lasting liver infection caused by the hepatitis B virus (HBV). It can lead to serious liver problems if left untreated.
- Chronic Hepatitis D Infection: Also known as hepatitis delta, this is a severe form of viral hepatitis caused by the hepatitis D virus (HDV). It only occurs in people who are also infected with hepatitis B.
How BJT-778 Works
While the exact mechanism of action is not fully described in the provided information, BJT-778 is being studied for its antiviral activity against both hepatitis B and hepatitis D viruses. The drug aims to reduce the levels of these viruses in the body and improve liver health.
Clinical Trial Details
The clinical trial for BJT-778 is a Phase 1/2a study, which means it's in the early stages of testing in humans. Here are some key points about the trial:
- It's a randomized, placebo-controlled study, which helps determine if the drug is effective compared to no treatment.
- The study includes both healthy volunteers and patients with chronic hepatitis B, including some with chronic hepatitis D.
- The main goal is to evaluate the safety and tolerability of BJT-778.
- Secondary goals include studying how the drug moves through the body (pharmacokinetics), how the immune system responds to it (immunogenicity), and how well it works against the hepatitis B and D viruses.
Eligibility Criteria
The study has specific criteria for who can participate. Some key inclusion criteria are:
- Adults aged 18-70 years
- Chronic hepatitis B infection for at least 6 months
- Currently on specific antiviral medications for hepatitis B
- For some groups, detectable levels of hepatitis D virus
There are also several exclusion criteria, such as having cirrhosis, other liver diseases, or certain medical conditions that might interfere with the study.
Safety and Effectiveness
The primary focus of this study is to assess the safety of BJT-778. Researchers will be monitoring:
- Side effects that occur during treatment
- Changes in laboratory test results
- The body's immune response to the drug
To measure effectiveness, the study will look at:
- Reduction in hepatitis B surface antigen (HBsAg) levels
- Reduction in hepatitis D virus RNA levels
- Changes in liver enzyme levels (ALT)
Administration
BJT-778 is given as a subcutaneous injection, which means it's injected just under the skin. The exact dosing schedule and duration of treatment will be determined as part of the clinical trial.